Stock Traders Purchase Large Volume of Call Options on ClearPoint Neuro (NASDAQ:CLPT)

ClearPoint Neuro, Inc. (NASDAQ:CLPT) saw some unusual options trading activity on Wednesday. Investors purchased 5,503 call options on the company. This represents an increase of 2,033% compared to the typical daily volume of 258 call options.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CLPT. Wall Street Zen upgraded shares of ClearPoint Neuro from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Stifel Nicolaus upped their target price on shares of ClearPoint Neuro from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $19.67.

ClearPoint Neuro Stock Performance

Shares of NASDAQ:CLPT opened at $19.28 on Thursday. The company has a market capitalization of $548.13 million, a price-to-earnings ratio of -23.80 and a beta of 0.89. ClearPoint Neuro has a 12 month low of $9.76 and a 12 month high of $20.94. The firm’s 50-day moving average is $11.04 and its 200 day moving average is $11.98. The company has a current ratio of 7.30, a quick ratio of 6.45 and a debt-to-equity ratio of 1.46.

ClearPoint Neuro (NASDAQ:CLPT) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The firm had revenue of $9.22 million for the quarter, compared to the consensus estimate of $9.20 million. ClearPoint Neuro had a negative net margin of 66.15% and a negative return on equity of 94.44%. ClearPoint Neuro has set its FY 2025 guidance at EPS. Research analysts predict that ClearPoint Neuro will post -0.66 EPS for the current year.

Institutional Investors Weigh In On ClearPoint Neuro

Several large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC lifted its position in shares of ClearPoint Neuro by 156.3% in the 1st quarter. Millennium Management LLC now owns 741,193 shares of the company’s stock worth $8,813,000 after purchasing an additional 452,043 shares during the period. Geode Capital Management LLC lifted its position in ClearPoint Neuro by 107.3% during the second quarter. Geode Capital Management LLC now owns 624,800 shares of the company’s stock valued at $7,461,000 after acquiring an additional 323,429 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in ClearPoint Neuro by 98.3% during the first quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company’s stock valued at $3,066,000 after acquiring an additional 127,823 shares during the last quarter. Bank of America Corp DE lifted its position in ClearPoint Neuro by 315.0% during the second quarter. Bank of America Corp DE now owns 113,698 shares of the company’s stock valued at $1,358,000 after acquiring an additional 86,304 shares during the last quarter. Finally, Lane Generational LLC lifted its position in ClearPoint Neuro by 53.5% during the first quarter. Lane Generational LLC now owns 242,045 shares of the company’s stock valued at $2,878,000 after acquiring an additional 84,350 shares during the last quarter. 30.08% of the stock is owned by hedge funds and other institutional investors.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.